Welcome to our dedicated page for STERIS plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on STERIS plc stock.
STERIS plc (NYSE: STE) is a leading global provider of infection prevention and procedural surgical products and services, primarily serving healthcare, pharmaceutical, research, and medical device customers. With a mission to create a healthier today and a safer tomorrow, the company delivers innovative infection prevention, decontamination, and health science technologies that support patient care and safety.
Founded in 1985 as Innovative Medical Technologies and rebranded as STERIS in 1987, the company’s history traces back to 1894 with the American Sterilizer Company, a pioneer in sterilization products. Today, STERIS is headquartered in Dublin, Ireland, and has positioned itself as a formidable force in the industry through strategic acquisitions and continuous innovation.
STERIS operates through several segments:
- Healthcare Services: Constituting approximately 70% of total revenue, this segment includes sterilizers, washer-disinfectors, and other decontamination equipment for healthcare facilities and biopharmaceutical manufacturing sites.
- Applied Sterilization Technologies (AST): Generating 19% of revenue, AST provides contract sterilization services for single-use and implantable medical devices globally.
- Life Sciences Services: Accounting for about 11% of revenue, this segment offers services and products for research and pharmaceutical environments.
In recent developments, STERIS has signed a definitive agreement to acquire surgical and sterilization assets from Becton, Dickinson and Company (BD) for $540 million. This acquisition, expected to close by September 2023, will expand STERIS’s product offerings within its Healthcare segment, focusing on operating rooms and sterile processing departments.
Financially, STERIS has demonstrated robust growth. For the first quarter of fiscal 2024, revenue increased by 11% to $1.28 billion, driven by improvements in procedure volumes and easing of supply chain challenges. The company continues to show strength across its segments, particularly in Healthcare, which saw a 17% growth in revenue to $818.9 million.
Moreover, STERIS is undergoing a targeted restructuring plan in its Healthcare surgical business in Europe, aiming to enhance its operational efficiency. This includes product rationalizations and facility consolidations, signaling a commitment to long-term profitability and growth.
STERIS remains committed to its vision of creating a safer world through continuous innovation and strategic expansions, making it a key player in the global healthcare industry.
STERIS plc (NYSE: STE) reported a 1% increase in revenue to $1.22 billion for fiscal Q3 2023, compared to $1.21 billion in the previous year. Constant currency organic revenue grew 7%. Earnings per share were $1.24 as reported, with adjusted EPS at $2.02. The company experiences challenges in supply chain and a slower growth in bioprocessing, impacting overall performance. STERIS updated its fiscal 2023 outlook, now expecting 6% revenue growth (previously 8%) and adjusted EPS guidance of $8.00 to $8.10.
STERIS plc (NYSE: STE) announced a quarterly interim dividend of $0.47 per share, payable on March 23, 2023, to shareholders of record as of February 24, 2023. STERIS is recognized as a leading global provider focusing on products and services that enhance patient care and infection prevention. This dividend demonstrates the company’s commitment to returning value to shareholders while reinforcing its role in creating a healthier and safer world through innovative solutions in healthcare and life sciences.
STERIS plc (NYSE: STE) will host a conference call to discuss its fiscal 2023 third quarter financial results on February 9, 2023, at 10:00 a.m. ET. The call will be accessible via the STERIS investor relations website or by phone. A detailed press release regarding the financial results will be issued after the U.S. market closes on February 8, 2023. For those unable to attend, a replay will be available starting at noon on February 9. STERIS is recognized for its infection prevention products and services aimed at supporting patient care.
STERIS plc (NYSE: STE) reported its fiscal 2023 second quarter results, showing revenue was flat at $1.2 billion year-over-year, with a 7% increase in constant currency organic revenue. The company incurred a net loss of $315.3 million, or ($3.15) per share, due to a $490.6 million impairment charge related to its Dental segment. Adjusted earnings per diluted share remained steady at $1.99. The company anticipates foreign currency headwinds affecting revenue growth, now expected to be 8%, down from 9%. Free cash flow projections decreased to $600 million from $675 million.
STERIS plc (NYSE: STE) has declared a quarterly interim dividend of $0.47 per share, which will be paid on December 16, 2022, to shareholders on record by November 22, 2022. This reinforces STERIS's commitment to shareholder returns while they continue to provide innovative healthcare solutions focusing on infection prevention. The company is a prominent player in enhancing patient care and safety globally.
STERIS plc (NYSE: STE) will host a conference call on November 10, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 second quarter financial results. A press release with these results will be released after market close on November 9, 2022. Investors can join the call via the website or by phone. A replay will be available afterward. STERIS specializes in products and services that enhance patient care and infection prevention globally. For further details, visit www.steris.com.
STERIS plc (NYSE: STE) reported a strong performance in its fiscal 2023 first quarter, ending June 30, with a 19% increase in revenue to $1.2 billion compared to $968.4 million in Q1 fiscal 2022. Adjusted EPS was $1.90, up from $1.76 a year ago. The company noted significant growth in its Healthcare segment, with a 16% revenue rise driven by consumables and capital equipment. Despite challenges, STERIS projected a 10% organic revenue growth and adjusted EPS guidance of $8.40 to $8.60 for the fiscal year.
STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.47 per share, marking a $0.04 increase. This is the Company's 17th consecutive year of dividend growth. The dividend will be payable on September 23, 2022, to shareholders on record as of September 7, 2022. STERIS is recognized as a leading global provider of products and services aimed at enhancing patient care, particularly focusing on infection prevention.
STERIS plc (NYSE: STE) will host a conference call on August 3, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 first quarter financial results. A press release with detailed results will be issued after the U.S. market closes on August 2, 2022. Investors can access the live call via the company’s website or by phone. A replay of the call will be available starting at 12:00 p.m. ET on the same day. STERIS provides innovative healthcare products and services, focusing on infection prevention to promote a healthier world.
STERIS plc reported a 39% increase in fourth quarter revenue for fiscal 2022, reaching $1.2 billion compared to $873.5 million in the prior year. The adjusted EPS stood at $2.04, up from $1.63. Healthcare revenue rose 32%, aided by acquisitions, while Applied Sterilization Technologies and Life Sciences segments also showed strong growth. However, full-year net income decreased to $243.9 million or $2.48 per diluted share, affected by $654 million in acquisition-related expenses. Looking ahead, STERIS expects 11% organic revenue growth in FY2023.
FAQ
What is the current stock price of STERIS plc (STE)?
What is the market cap of STERIS plc (STE)?
What does STERIS plc specialize in?
Where is STERIS plc headquartered?
What are the main business segments of STERIS plc?
How much of STERIS’s revenue comes from Healthcare Services?
What recent acquisition has STERIS plc announced?
What was STERIS’s revenue growth in the first quarter of fiscal 2024?
What is the anticipated revenue growth for fiscal 2024?
What restructuring efforts is STERIS undertaking?
What percentage of STERIS’s revenue is derived from Applied Sterilization Technologies (AST)?
When was STERIS plc originally founded?
